AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2019 Healthcare Licensing Analytical Report with Focus on Biosimilars - ResearchAndMarkets.com

May 8, 2019

DUBLIN--(BUSINESS WIRE)--May 8, 2019--The “Analytical Report for Healthcare Licensing with focus on Biosimilars” report has been added to ResearchAndMarkets.com’s offering.

In an environment where health decisions are increasingly made based on value and cost, biosimilars play a vital role in improving patient access to needed medicine. 50+ licensing news with focus on Biosimilars are reported and analyzed to provide a snapshot view of the current business trends here.

Analytical data coverage:

  • January 1, 2018 to March 31, 2019 licensing deals and negotiations
  • 50+ worldwide Biosimilars focused healthcare licensing news of companies across North America (33%), Europe (23%), Asia (41%)
  • Small-mid-large cap companies covered - LargeCap (73%)
  • Listed and non-listed companies included (click here to view a sample list of 30 companies/institutes covered)
  • 4 healthcare sub-sectors covered - Pharmaceuticals (59%), Biotech (33%), Healthcare Services (2%), Medical Devices (3%)
  • 14 medicine groups studied - Oncology (26%), Rheumatology (18%), Hematology (11%)
  • 8+ variables analyzed

User benefits:

  • Immediate access to current global licensing trends for Biosimilars
  • Succinct summaries of licensing deals and negotiations held worldwide
  • Quick to-the-point analytical references
  • In-depth updates on wider perspective of Biosimilars
  • Directions to the emerging business prospects

Key analysis in the report:

  • Leading countries in Biosimilars focused licensing
  • Most active healthcare sub-sectors in Biosimilars focused licensing
  • Distribution of Biosimilars focused licensing deals among market cap groups
  • Comparisons of different medicine groups in Biosimilars focused licensing
  • Companies currently engaging the most in Biosimilars focused licensing
  • Dynamics of varied licensing payments arrangements worldwide

Report useful to:

  • Biosimilars focused healthcare companies seeking licensing opportunities
  • Biosimilars focused healthcare companies seeking new market base
  • Executives of healthcare companies negotiating licensing for Biosimilars
  • Investors analyzing varied kinds of transaction options for Biosimilars focused licensing

Key Topics Covered

Introduction

Research Design

Chapter 1: Analysis of healthcare inventions with focus on Biosimilars licensed during the past five quarters

1.1 Number of licensing deals with focus on Biosimilars

1.2 Countries with most licensing deals with focus on Biosimilars

1.3 Healthcare sub-sectors with most licensing deals with focus on Biosimilars

1.4 Market capitalization groups with most licensing deals with focus on Biosimilars

1.5 Medicine groups with most licensing deals with focus on Biosimilars

1.6 Leading companies with most licensing deals with focus on Biosimilars

1.7 Licensing payment arrangements most followed in licensing deals with focus on Biosimilars

Chapter 2: Key licensing deals with focus on Biosimilars during the past five quarters - By type of licensing deal

Chapter 3: Global healthcare inventions with focus on Biosimilars licensed during the past five quarters - By region and company name

Chapter 4: Summary and conclusions

Appendices

Appendix 1 List of companies/institutes covered

a) By region, country and company name

b) By sub-industry, country and company name

c) By market capitalization group, country and company name

d) By medicine group, country and company name

e) By terms of payment, country and company name

Appendix 2 List of non-listed companies covered - By country and company name

Appendix 3 List of not-for-profit institutes covered - By country and institute name

Companies Mentioned

Alphabetical List of Sample 30 Companies/Institutes (of the total 103 companies covered) in the Report:

  • Momenta Pharmaceuticals, Inc.
  • Mundipharma International Limited
  • Mundipharma Pte Ltd.
  • Mylan N.V.
  • NCPC GeneTech Biotechnology Development Co., Ltd.
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis AG
  • Orion Corporation
  • Pfenex Inc
  • Pfizer Inc.
  • PlantForm Corporation
  • Prestige BioPharma Pte Ltd
  • Proteomics International Laboratories Ltd.
  • Revance Therapeutics, Inc
  • Samsung Bioepis Co., Ltd.
  • Sandoz AG
  • Sandoz Inc
  • Sanofi SA
  • Sanofi-Aventis Deutschland GmbH
  • Sanwa Kagaku Kenkyusho Co., Ltd.
  • Selexis SA
  • Shandong Boan Biological Technology Co. Ltd
  • Shandong Luye Pharmaceutical Co., Ltd.
  • Shenzhen ChipScreen Biosciences, Ltd.
  • STADA Arzneimittel AG
  • Symphogen A/S Biotech
  • Thermo Fisher Scientific Inc.
  • Turgut Ilaclari A.S
  • Valerius Biopharma AG
  • Xbrane Biopharma AB

For more information about this report visit https://www.researchandmarkets.com/r/qn3gl3

View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005649/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Healthcare Services,Biosimilars and Biosuperiors

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/08/2019 12:19 PM/DISC: 05/08/2019 12:19 PM

http://www.businesswire.com/news/home/20190508005649/en